engleski

Addition of propolis or irinotecan therapy prolongs survival in ehrlich ascites tumor bearing mice

We investigated possible synergistic action of anticancer drug Irinotecan combined with ethanolic (EEP) and water-soluble (WSDP) derivate of propolis on Swiss albino mice injecetd with EAT. For survival analysis mice were administered WSDP and EEP (100 mg/kg) daily for three consecutive days, beginning on 3rd day after EAT cells (1x106) injection. Irinotecan was administered at a dose of 50 mg kg-1 on days 1, 13 and 19. We simultaneously studied peripheral White blood cells (WBC) count, cell types washed from the peritoneal cavity, functional activity of macrophages from peritoneal cavity and the level of primary DNA damage in leukocytes, kidney and liver cells using the alkaline comet assay. Three out of nine mice per group survived the entire duration of the experiment (90 days) in groups treated with Irinotecan combined with WSDP and EEP. All test components increased survival of mice by 7.53 to 231.54 %. Combined treatment with Irinotecan and/or WSDP and EEP significantly decreased percentage of tumour cells in the peritoneal cavity as compared to non-treated EAT injected mice. All treated animals had significantly higher percentage of neutrophils in the peritoneal cavity in comparison to non-treated EAT injected mice. We observed significantly higher value of DNA damage in leukocytes of mice treated with Irinotecan and combination of Irinotecan and/or WSDP and EEP as compared to non-treated EAT injected mice, while the same treatment decreased DNA damage in kidney. Our results showed that addition of propolis to Irinotecan treatment enhanced antitumor activity of Irinotecan and prolongs survival in Ehrlich ascites tumor bearing mice which definitely deserve further studies to clarify the possible mechanisms of antitumor actions of combined herb-drug treatments.

Ehrlich ascites tumor; Irinotecan; propolis; survival; tumor growth

nije evidentirano